Thermally processed polymeric microparticles for year-long delivery of dexamethasone

Goodfriend, Amy C.; Welch, Tre R; Nguyen, Kytai T.; Johnson, Romaine F.; Sebastian, Vinod A.; Reddy, Sunil; Forbess, Joseph M.; Nugent, Alan

doi:10.1016/j.msec.2015.09.003

Cited by 9 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to point out that in the calculation only the raw material costs are included, however, the calculation helps to identify the components influencing most significantly the cost of particle production. Main cost components result to be the polymer (51.15%) and the drug (35.45%) as reported also in previous works 15,50,53,[56][57][58] .…”

Section: Solidification Diffusion Velocitysupporting

confidence: 80%

“…It is well known that higher energy densities are needed to produce smaller droplets 54,55 . For that reason, results obtained in the present work by using the pulsed back-and-forward method are more relevant if we consider that the mean particle size (1.25 µm) is significantly smaller that the size reported by other membrane emulsification methods (60-120 µm) 50 or by conventional emulsification methods (15-80 µm) 15,56,57 . Slightly smaller particles (mean particle size = 0.4-0.6 µm) with high throughput (3 10 -7 m 3 s -1 ) were produced by using the sonicator in the emulsification step but with a significant increase in the energy consumption (from 10 5 Jm -3 by using pulsed-back-and-forward membrane emulsification to 10 8 Jm -3 by using a sonicator).…”

Section: Solidification Diffusion Velocitymentioning

confidence: 52%

“…Green metric factors obtained for the method developed in the present work were compared with the same data calculated for the method described by Gu and Burgess 15 . This paper was the only one that included data referred to both emulsification and solvent diffusion steps, while other papers analysed in this section only referred to the emulsification step 50,53,[56][57][58] sEF and cEF resulted to be quite similar and the most important difference was attributed to the amount of polymer and drug used. The ratio between sEF and cEF values (% cEF litd) is a helpful indicator for relative solvent usage and thus waste reduction potential.…”

Section: Solidification Diffusion Velocitymentioning

confidence: 99%

“…Similar analysis previously conducted in the pharmaceutical field confirms the higher contribution of solvents to the cumulative PMI. The relative value of solvent and water percentages associated with the production of active ingredients from a survey of several pharmaceutical companies was estimated to be 88% by the Pharmaceutical Roundtable 57 . In contrast, the results for the commercial route show a lower relative value of solvent and water percentage solvent of 78% 58 .…”

Section: Solidification Diffusion Velocitymentioning

confidence: 99%

See 3 more Smart Citations

Sustainable Production of Drug-Loaded Particles by Membrane Emulsification

Albisa

Piacentini

Arruebo

et al. 2018

ACS Sustainable Chem. Eng.

View full text Add to dashboard Cite

As the field of drug delivery is expanding into consumer products, it is essential to advance in the development of efficient synthesis technologies while preserving, at the same time, human health and the environment for future generations. Here, the sustainable development of polymeric particles for drug delivery is described. Poly(ethylene glycol) methyl ether-block-poly(lactide-coglycolide) based particles containing dexamethasone were produced by membrane emulsificationsolvent diffusion methods. The ability of the synthesis process to control particle-size distribution and morphology and its green impactful (energy consumption, simple (sEF) and complete (cEF) E factor) were evaluated. Particles with sufficiently narrow distribution in their droplet size and mean diameter similar to the membrane pore diameter were produced by increasing the dispersed phase flux to 12.84 L h-1 m-2 , minimizing the maximum shear stress to 1.12 Pa and the energy consumption to 3.96 10 5 Jm-3. The impact of the solvent used on size distribution, particles morphology and green performance scores was also studied. More uniform particles, with dense and slightly rough surface, high encapsulation efficiency and drug loading were obtained by replacing Dichloromethane with Ethyl acetate. The E factor was also decreased by 80%. Results demonstrated that membrane emulsification is an environmentally improved method for the production of drug delivery systems with enormous impact in terms of formulation quality, energy consumption reduction and waste minimization.

show abstract

Section: Solidification Diffusion Velocitysupporting

confidence: 80%

Section: Solidification Diffusion Velocitymentioning

confidence: 52%

Section: Solidification Diffusion Velocitymentioning

confidence: 99%

Section: Solidification Diffusion Velocitymentioning

confidence: 99%

See 2 more Smart Citations

Sustainable Production of Drug-Loaded Particles by Membrane Emulsification

Albisa

Piacentini

Arruebo

et al. 2018

ACS Sustainable Chem. Eng.

View full text Add to dashboard Cite

show abstract

“…Despite of these exciting findings, compound SA-2 undergoes fast hydrolysis (t 1/2 less than one day at pH 7.4 ), which is common for most of the 1,3,5-oxadiazoles containing “spontaneous” NO donating compounds 25 . To improve the therapeutic bioavailability and the aqueous chemical stability of SA-2, it was encapsulated into FDA approved PLGA nanocarriers using a standard emulsion method similar to our previous studies 30 – 33 . PLGA NPs have been shown to protect degradation and inactivity of various therapeutic reagents, including SA-2, and to extend the therapeutic efficacy as observed by other investigators and our group.…”

Section: Resultsmentioning

confidence: 99%

Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases

Kuriakose

Nguyen

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

Nitric oxide (NO) has been known to promote physiological angiogenesis to treat peripheral arterial diseases (PAD) by increasing the vascular endothelial growth factor (VEGF) level in endothelial cells (ECs) and preventing platelet adherence and leukocyte chemotaxis. However, the ongoing ischemic event during peripheral ischemia produces superoxide and diminishes the NO bioavailability by forming toxic peroxynitrite anion. Here we disclose an efficacious hybrid molecule 4-(5-Amino-1,2,3-oxadiazol-3-yl)-2,2,6,6-tetramethyl-1-piperidinol (SA-2) containing both antioxidant and NO donor functionalities that provide a therapeutic level of NO necessary to promote angiogenesis and to protect ECs against hydrogen peroxide-induced oxidative stress. Compound SA-2 scavenged reactive oxygen species, inhibited proliferation and migration of smooth muscle cells (SMCs) and promoted the tube formation from ECs. Copolymer poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with SA-2 provided a sustained release of NO over days, improved aqueous stability in serum, protected ECs against oxidative stress, and enhanced angiogenesis under stress conditions as compared to that of the control in the in vitro matrigel tube formation assay. These results indicated the potential use of SA-2 nanoparticles as an alternative therapy to treat PAD.

show abstract

New Poly[(R )-3-hydroxybutyrate-co -4-hydroxybutyrate] (P3HB4HB)-Based Thermogels

Wee

Liow

Liu

et al. 2017

Macromol. Chem. Phys.

View full text Add to dashboard Cite

Poly[(R)‐3‐hydroxybutyrate] (P3HB) is a potential candidate for biomaterials due to its biocompatibility and biodegradability. However, P3HB needs to have tunable hydrophobicity, modification through chemical functionalization and the right hydrolytic stability to increase their potential for water‐based biomedical applications such as using them as in situ forming gels for drug delivery. This work focuses on using a copolymer, poly[(R)‐3‐hydroxybutyrate‐co‐4‐hydroxybutyrate] (P3HB4HB) in a thermogelling multiblock system with polypropylene glycol and polyethylene glycol to study the effect of the hydrophobic P3HB4HB on gelation properties, degradation, and drug release rates with reference to P3HB. Thermogels containing P3HB4HB segments show lower critical micellization concentration values in a range from 3 × 10−4 to 1.08 × 10−3 g mL−1 and lower critical gelation concentration values ranging from 2 to 6 wt% than that of gels containing P3HB. Furthermore, gels containing P3HB4HB degrade at a slower rate than the gels containing P3HB. Drug release studies of 5 µg mL−1 of doxorubicin show that gels containing P3HB4HB exhibit sustained release although the release rates are faster than gels containing P3HB. However, this can be modified by varying the concentration of the gels used. Process optimization of purifying the starting material is one important factor before the synthesis of these biomaterials.

show abstract

Thermally processed polymeric microparticles for year-long delivery of dexamethasone

Cited by 9 publications

References 29 publications

Sustainable Production of Drug-Loaded Particles by Membrane Emulsification

Sustainable Production of Drug-Loaded Particles by Membrane Emulsification

Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases

New Poly[(R )-3-hydroxybutyrate-co -4-hydroxybutyrate] (P3HB4HB)-Based Thermogels

Contact Info

Product

Resources

About